NCT05093881 Long-term Follow-up of Patients With Alcoholic Liver Cirrhosis Who Had Administered Cellgram-LC in PMC-P-07 Study
| NCT ID | NCT05093881 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Pharmicell Co., Ltd. |
| Condition | Alcoholic Cirrhosis |
| Study Type | INTERVENTIONAL |
| Enrollment | 100 participants |
| Start Date | 2021-08-24 |
| Primary Completion | 2026-08-24 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 100 participants in total. It began in 2021-08-24 with a primary completion date of 2026-08-24.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This Long-term follow-up is designed to evaluate the safety of patient with Alcoholic Liver Cirrhosis who had administered Cellgram-LC in PMC-P-07 study.
Eligibility Criteria
Inclusion Criteria: 1. Those who participated in PMC-P-07 clinical trials and received Cellgram-LC 2. Those who voluntarily agreed in writing to participate in this investigation Exclusion Criteria: \-
Contact & Investigator
Moonyoung Kim
PRINCIPAL INVESTIGATOR
Wonju Severance Christian Hospital
Frequently Asked Questions
Who can join the NCT05093881 clinical trial?
This trial is open to participants of all sexes, studying Alcoholic Cirrhosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05093881 currently recruiting?
Yes, NCT05093881 is actively recruiting participants. Contact the research team at jyjeong@pharmicell.com for enrollment information.
Where is the NCT05093881 trial being conducted?
This trial is being conducted at Bucheon-si, South Korea, Cheonan, South Korea, Chuncheon, South Korea, Chuncheon, South Korea and 7 additional locations.
Who is sponsoring the NCT05093881 clinical trial?
NCT05093881 is sponsored by Pharmicell Co., Ltd.. The principal investigator is Moonyoung Kim at Wonju Severance Christian Hospital. The trial plans to enroll 100 participants.